This paper presents a methodology to maximize the self-sufficiency or cost-effectiveness of grid-connected prosumers by optimizing the sizes of photovoltaic (PV) systems and electrochemical batteries. In the optimal sizing procedure, a limitation on the maximum injection in the grid can affect the energy flows, the economic effectiveness of the investments, and thus the sizing results. After the explanation of the procedure, a case study is presented, and a parametric analysis of the effect of possible injection limits is shown. The procedure is applied to size plants for an Italian domestic prosumer, whose electric load profile was measured for a year. A software program developed using the proposed methodology is also briefly presented. It is used for both research and educational purposes, both in laboratory classes and in remote lessons.

During their operational life, photovoltaic (PV) modules may exhibit various defects for poor sorting of electrical performance during manufacturing, mishandling during transportation and installation, and severe thermo-mechanical stresses. Electroluminescence testing and infrared thermographic imaging are the most common tests for checking these defects, but they are only economically viable for large PV plants. The defects are also manifested as abnormal electrical properties of the affected PV modules. For defect diagnosis, the appropriate parameters on their I-V curves are open circuit voltage, photo-generated current, series resistance, and the shunt resistance. The health of PV modules can be assessed by calculating these values and comparing them with the reference parameters. If these defects are diagnosed in time, the power loss is avoided and safety hazards are mitigated. This paper first presents a review of common defects in PV modules and then a review of the methods used to find the above-mentioned parameters during the normal PV operation. A simple approach to determine the resistances of the equivalent circuit is discussed. Finally, through a modification in an ordinary maximum power point tracking (MPPT) algorithm, information about the state of health of PV modules is obtained. This method is effective, especially if applied to submodule-integrated MPPT architectures.

No abstract

No abstract

The pharmacokinetic profile of ZST316 and ZST152, arginine analogues with inhibitory activity towards human dimethylarginine dimethylaminohydrolase-1 (DDAH1), was investigated in mice using a newly developed HPLC-MS/MS method. The method proved to be reproducible, precise, and accurate for the measurement of the compounds in plasma and urine. Four-week-old female FVB mice received a single dose of ZST316 and ZST152 by intravenous bolus (30 mg/Kg) and oral gavage (60 mg/Kg). ZST316 Cmax was 67.4 µg/mL (intravenous) and 1.02 µg/mL (oral), with a half-life of 6 h and bioavailability of 4.7%. ZST152 Cmax was 24.9 µg/mL (intravenous) and 1.65 µg/mL (oral), with a half-life of 1.2 h and bioavailability of 33.3%. Urinary excretion of ZST152 and ZST316 was 12.5%–22.2% and 2.3%–7.5%, respectively. At least eight urinary metabolites were identified. After chronic intraperitoneal treatment with the more potent DDAH1 inhibitor, ZST316 (30 mg/Kg/day for three weeks), the bioavailability was 59% and no accumulation was observed. Treatment was well tolerated with no changes in body weight vs. untreated animals and no clinical signs of toxicity or distress. The results of this study show that ZST316 has a favorable pharmacokinetic profile, following intraperitoneal administration, to investigate the effects of DDAH1 inhibition in mice.